Ablynx Nv (ABLYF) 9.9200 $ABLYF
Ablynx's (ABLYF) CEO Edwin Moses on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 26, 2:19PM CST
Small companies lead the I-O class of Cancer Therapies
ACCESSWIRE - Fri Aug 08, 7:02AM CDT
Los Angeles, CA / August 8, 2014 / Tumor cells, tending to persist after treatment, lead to remission and have been a bane to cancer researchers and doctors for decades. Only recently, immuno-oncology, labeled 'I-O' first by Bristol-Myers Squibb Company (NYSE:BMY) has emerged to become a new class of cancer medicines that may someday take a meaningful place alongside chemotherapy, surgery, and radiation.
CLSN: 2.60 (+0.08), NWBO: 8.30 (-0.14), CVM: 0.99 (-0.01), CLDX: 28.56 (+1.10), INCY: 93.81 (+1.53), AZN: 69.91 (-0.25), MRK: 57.25 (-0.18), NLNK: 55.38 (-0.33), PPHM: 1.40 (+0.02), BMY: 64.64 (+1.18), FPRX: 20.98 (+0.96)
PUBLICATION IN ACCORDANCE WITH ARTICLE 15 OF THE BELGIAN LAW OF 2 MAY 2007 ON THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW"
GlobeNewswire - Thu Jul 03, 11:07AM CDT
Ablynx [Euronext Brussels: ABLX] announces that the closing of its private placement ("Accelerated Bookbuild Offering"/"ABO" took place today and as a result, Ablynx issued 4,908,332 new shares.
Ablynx's (ABLYF) CEO Edwin Moses on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Feb 26, 2:19PM CST
Small companies lead the I-O class of Cancer Therapies
ACCESSWIRE - Fri Aug 08, 7:02AM CDT
Los Angeles, CA / August 8, 2014 / Tumor cells, tending to persist after treatment, lead to remission and have been a bane to cancer researchers and doctors for decades. Only recently, immuno-oncology, labeled 'I-O' first by Bristol-Myers Squibb Company (NYSE:BMY) has emerged to become a new class of cancer medicines that may someday take a meaningful place alongside chemotherapy, surgery, and radiation.
CLSN: 2.60 (+0.08), NWBO: 8.30 (-0.14), CVM: 0.99 (-0.01), CLDX: 28.56 (+1.10), INCY: 93.81 (+1.53), AZN: 69.91 (-0.25), MRK: 57.25 (-0.18), NLNK: 55.38 (-0.33), PPHM: 1.40 (+0.02), BMY: 64.64 (+1.18), FPRX: 20.98 (+0.96)
PUBLICATION IN ACCORDANCE WITH ARTICLE 15 OF THE BELGIAN LAW OF 2 MAY 2007 ON THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW"
GlobeNewswire - Thu Jul 03, 11:07AM CDT
Ablynx [Euronext Brussels: ABLX] announces that the closing of its private placement ("Accelerated Bookbuild Offering"/"ABO"
took place today and as a result, Ablynx issued 4,908,332 new shares. 
